HK1208470A1 - Biomarkers for use in integrin therapy applications - Google Patents

Biomarkers for use in integrin therapy applications

Info

Publication number
HK1208470A1
HK1208470A1 HK15107088.1A HK15107088A HK1208470A1 HK 1208470 A1 HK1208470 A1 HK 1208470A1 HK 15107088 A HK15107088 A HK 15107088A HK 1208470 A1 HK1208470 A1 HK 1208470A1
Authority
HK
Hong Kong
Prior art keywords
biomarkers
therapy applications
integrin therapy
integrin
applications
Prior art date
Application number
HK15107088.1A
Other languages
English (en)
Chinese (zh)
Inventor
Shelia M Violette
Dean Sheppard
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HK1208470A1 publication Critical patent/HK1208470A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15107088.1A 2012-03-29 2015-07-24 Biomarkers for use in integrin therapy applications HK1208470A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617451P 2012-03-29 2012-03-29
US201261648199P 2012-05-17 2012-05-17
PCT/US2013/032082 WO2013148316A1 (en) 2012-03-29 2013-03-15 Biomarkers for use in integrin therapy applications

Publications (1)

Publication Number Publication Date
HK1208470A1 true HK1208470A1 (en) 2016-03-04

Family

ID=49261073

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107088.1A HK1208470A1 (en) 2012-03-29 2015-07-24 Biomarkers for use in integrin therapy applications

Country Status (5)

Country Link
US (3) US20150086570A1 (xx)
EP (1) EP2831104B1 (xx)
ES (1) ES2875535T3 (xx)
HK (1) HK1208470A1 (xx)
WO (1) WO2013148316A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
AU2013221585B2 (en) 2012-02-17 2017-03-30 Seagen Inc. Antibodies to integrin alphavbeta6 and use of same to treat cancer
AU2013284448B2 (en) 2012-06-27 2019-04-18 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
PL228091B1 (pl) * 2014-02-12 2018-02-28 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro
MX2017002229A (es) 2014-08-19 2017-05-09 Merck Sharp & Dohme Anticuerpos anti tigit.
WO2016094425A1 (en) 2014-12-08 2016-06-16 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2017030823A2 (en) * 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2017054058A1 (en) 2015-09-30 2017-04-06 Immunexpress Pty Ltd Pathogen biomarkers and uses therefor
US20180321242A1 (en) * 2015-11-06 2018-11-08 Immunexpress Pty Ltd Viral biomarkers and uses therefor
WO2017190218A1 (en) * 2016-05-06 2017-11-09 University Health Network Liquid-biopsy signatures for prostate cancer
AU2017327828B2 (en) * 2016-09-16 2023-11-16 Shanghai Henlius Biotech, Inc. Anti-PD-1 antibodies
CN106636330B (zh) * 2016-09-21 2017-12-15 郁金泰 阿尔茨海默病的诊断和治疗药物
WO2021041317A1 (en) * 2019-08-23 2021-03-04 University Of Virginia Patent Foundation Ddx17 and nlrc4 targeting for inflammatory diseases
AU2020397070A1 (en) 2019-12-05 2022-07-14 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511738A4 (en) * 2002-05-17 2007-05-09 Scios Inc TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS
DE602004014795D1 (de) * 2003-10-01 2008-08-14 Merck Patent Gmbh Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
US20070292887A1 (en) * 2003-11-04 2007-12-20 Bayer Pharmaceuticals Corporation Immunohistochemical Methods
WO2005069935A2 (en) * 2004-01-20 2005-08-04 University Of Medicine And Dentistry Of New Jersey METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
EP2046374A4 (en) 2006-07-10 2010-05-05 Biogen Idec Inc COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS
AU2007354317A1 (en) * 2006-10-19 2008-12-04 Biogen Idec Ma Inc. Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6
GB0803192D0 (en) * 2008-02-22 2008-04-02 Mubio Products Bv SCLC biomarker panel
EP2706358A3 (en) * 2008-12-23 2014-05-07 Merck Patent GmbH Biomarkers for inhibitors with anti-angiogenic activity
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles

Also Published As

Publication number Publication date
US20150086570A1 (en) 2015-03-26
ES2875535T3 (es) 2021-11-10
EP2831104B1 (en) 2021-04-21
EP2831104A4 (en) 2015-09-16
US20200248257A1 (en) 2020-08-06
WO2013148316A1 (en) 2013-10-03
EP2831104A1 (en) 2015-02-04
US20220049301A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
HK1208470A1 (en) Biomarkers for use in integrin therapy applications
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1203493A1 (en) Substituted azabicycles and use thereof
EP2836608A4 (en) TUBERCULOSIS BIOMARKERS AND USES THEREOF
EP2843024A4 (en) BRIEF POLYGLYCOLIC ACID RESIN FIBERS FOR USE OF A DRILLING TREATMENT LIQUID
HK1210949A1 (en) Combinations and uses thereof
EP2819749A4 (en) BIOMARKERS ASSOCIATED WITH AUTISM AND USES THEREOF
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
EP2872973A4 (en) IMPROVEMENTS IN DEVICES FOR USE WITH COMPUTERS
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
SG11201405814WA (en) Improvements in fluid conditioning
GB201211158D0 (en) Biomarkers and uses thereof
HK1203232A1 (en) Biomarker and use thereof
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
GB201218438D0 (en) Biomarkers and uses thereof
EP2922862A4 (en) COMPLEX FORMING MODULATING ACTIVE SUBSTANCES AND USES THEREOF
GB201202593D0 (en) All in one
GB201217715D0 (en) Improvements in swimfeeder devices
GB201210602D0 (en) Improvement in compsite materials
GB201222541D0 (en) Kiddibidet and pottibidet
GB201206393D0 (en) Use
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201222457D0 (en) Reversed mode
GB201114341D0 (en) Reagent and use